16/06/2016
A new implantable device offers promise for patients with moderate to severe obstructive (OSA) who cannot tolerate continuous positive airway pressure, the most commonly used treatment for OSA. After a successful initial clinical trial in 2014, a new case study conducted by U.S. researchers has now demonstrated that the device notably reduces the symptoms of OSA.
DENVER/PHILADELPHIA, USA: A new implantable device offers promise for patients with moderate to severe obstructive sleep apnea (OSA) who cannot tolerate continuous positive airway pressure (CPAP), the most commonly used treatment for OSA. After a successful initial clinical trial in 2014, involving…